Tolebrutinib Phase 3 Trials in MS
A randomized, double-blind Ph3 RMS trial to assess efficacy of once-daily tolebrutinib vs 14mg teriflunomide measured by ARR, as well as disability progression, MRI, cognition, QoL, safety, pharmacodynamics, and pharmacokinetics.
This study has been fully enrolled. Data presented at ECTRIMS 2024.
Additional Resources
COMPOUND*
CATEGORY*
KEYWORD*
KEYWORD
*indicates a required field
Results ()
All
+
Publications
+
Videos
+
Posters
+
Websites
+
Can’t find what you’re looking for?
Find an MSL near you.
MAT-US-2308934 v3.0-P
Exp. Date 12/06/2026©2024 Sanofi. All rights reserved.Sanofi is a registered trademark of Sanofi or an affiliate.
Additional Resources
Resource Library
COMPOUND*
CATEGORY*
KEYWORD*
KEYWORD
*indicates a required field
Results ()
All
Publications
Videos
Posters
Websites
MAT-US-2308934 v3.0-P
Exp. Date 12/06/2026©2024 Sanofi. All rights reserved.Sanofi is a registered trademark of Sanofi or an affiliate.